Home » Waters Introduces The New ACQUITY UPLC I-Class
Waters Introduces The New ACQUITY UPLC I-Class
Waters Corporation today introduced the ACQUITY UPLC I-Class System, a high-performing UPLC system. For scientists challenged by the most difficult separations, the company says, the I-Class features the lowest system dispersion and lowest carryover in the industry today. Low dispersion maximizes peak capacity thereby advancing chromatographic separations and optimizing the performance of any mass spectrometer.
“The scientific discoveries with the biggest potential to improve our lives often rely on samples and compounds that are the most difficult to understand. The ACQUITY UPLC I-Class System was designed specifically for the rapid pace of laboratories on the cutting edge of research,” said Art Caputo, President of the Waters Division. “Design and function of the I-Class are based on continuous customer input resulting in improvements in sub-two-micron separation that only the originator of the technology can exploit. Whether customers need to rapidly analyze sample-limited compounds amid a complex matrix or they seek to optimize the performance of any mass spectrometer on the market, ACQUITY UPLC I-Class enables scientists to solve their most complex separations and detection challenges.”
Keeping pace with today’s most advanced laboratories, the ACQUITY UPLC I-Class System excels when analyzing complex, sample-limited compounds. Sample-limited compounds include high potency medications, trace levels of food or water contamination, and (advanced) sophisticated biotherapeutics. These samples can represent complex separation challenges requiring an LC system that can maximize the benefits of sub-two-micron for faster throughput and optimized MS performance.
While there are many innovations built into the new ACQUITY UPLC I-Class, minimal system volume is a new key feature. Reduced system volume significantly decreases dispersion rates for reproducibly higher resolution and superior peak capacity. Reduced dispersion and small peak volumes extend the sensitivity of any mass spectrometer. Additionally, low dispersion footprint allows users to reduce their separation cycle times without impact to the separation as resolution is maintained even for ballistic gradients lasting less than one minute. Also importantly, new design and materials dramatically reduce sample carryover effects, thus increasing user confidence in results.
The ACQUITY UPLC I-Class also features class leading flexibility and precise sampling capabilities. Depending on application needs, users can choose either the highest precision and lowest dispersion fixed-loop Sample Manager, or the world’s first low dispersion variable volume Sample Manager with a flow-through needle design, which delivers high-precision injections, excellent sample recovery, and lowest sample carryover optimizing the performance for even the most sensitive mass detectors.
Aragon Purchased For $650M+From USA Today
Johnson & Johnson has agreed to buy Aragon Pharmaceuticals for at least $650 million in cash.
ASME BPE Certifies MaxPure Stainless-Steel Fittings
TEK Stainless Piping Products announces certification of MaxPure, EGMO’S stainless-steel fitting product line for bioprocessing industry
Supreme Court Rules Against 'pay-to-delay'From Economic Times
Big pharma companies lose in Supreme Court's 'pay-to-delay' decision.
BioScrip Acquires CarePoint for $223 MillionFrom Bloomberg Businessweek
BioScrip Inc. plans to expand its drug infusion business with a new acquisition of CarePoint for $223 million.
Endress+Hauser Offers Online Thermowell Sizing Calculator
Free, online thermowell calculation tool compliant with new ASME PTC 19.3 TW-2010 standards simplifies engineer work
Supreme Court DNA Ruling Could Hurt Biotech IndustryFrom The Denver Post Politics
Critics said the ruling would discourage other companies and financial backers from investing in more genetic sequencing research
Supreme Court Says No to Patenting Human GenesFrom The Scientist
The Court unanimously ruled that isolated sequences of human DNA are not eligible for patent protection, but artificial sequences can be patented
All-new Pharma EXPO Debuts in November 2014
Co-located with PACK-EXPO International, ISPE Pharma EXPO will be held in Chicago
Canadian Health Authority Accepts Use of Roche's Rapid Mycoplasma Detection TestFrom Roche
Roche’s Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
Over 200 Cardiovascular Disease Drugs in DevelopmentFrom Drug Store News
According a recent report, 215 drugs are now under development for heart disease and stroke.
- All news »